We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Abiomed, Inc (ABMD) is a leading medical devices business with stocks listed in the US. It opened the day at US$299.88 after a previous close of US$298.13. During the day the price has varied from a low of USD296.62 to a high of USD299.88. The latest price was USD299.19 (25 minute delay). Abiomed is listed on the NASDAQ. All prices are listed in US Dollars.
How to buy shares in Abiomed
- Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for Abiomed. Find the share by name or ticker symbol: ABMD. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Abiomed reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$289.51, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Abiomed, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Abiomed. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
What's in this guide?
- Abiomed key stats
- Compare share trading platforms
- Is Abiomed stock a buy or sell?
- Abiomed performance over time
- Can I short Abiomed shares?
- Are Abiomed shares over-valued?
- Abiomed's financials
- How volatile are Abiomed shares?
- Does Abiomed pay a dividend?
- Have Abiomed shares ever split?
- Other common questions
Abiomed share priceUse our graph to track the performance of ABMD stocks over time.
Abiomed shares at a glance
|52-week range||US$234.39 - US$355.94|
|50-day moving average||US$297.87|
|200-day moving average||US$307.5239|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||US$4.94|
Compare share trading platforms to buy stock
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
Is it a good time to buy Abiomed stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Abiomed price performance over time
|1 month (2021-05-13)||13.89%|
|3 months (2021-03-12)||-1.44%|
|6 months (2020-12-11)||15.76%|
|1 year (2020-06-12)||23.80%|
|2 years (2019-06-13)||17.09%|
|3 years (2018-06-13)||-30.91%|
|5 years (2016-06-13)||193.99%|
Is Abiomed under- or over-valued?
Valuing Abiomed stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Abiomed's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Abiomed's P/E ratio
Abiomed's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 59x. In other words, Abiomed shares trade at around 59x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Abiomed's PEG ratio
Abiomed's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.75. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Abiomed's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Abiomed's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$256.2 million.
The EBITDA is a measure of a Abiomed's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||US$847.5 million|
|Operating margin TTM||27.48%|
|Gross profit TTM||US$685.6 million|
|Return on assets TTM||10.74%|
|Return on equity TTM||18.83%|
|Market capitalisation||US$13.3 billion|
TTM: trailing 12 months
Shorting Abiomed shares
There are currently 756,114 Abiomed shares held short by investors – that's known as Abiomed's "short interest". This figure is 9% down from 830,622 last month.
There are a few different ways that this level of interest in shorting Abiomed shares can be evaluated.
Abiomed's "short interest ratio" (SIR)
Abiomed's "short interest ratio" (SIR) is the quantity of Abiomed shares currently shorted divided by the average quantity of Abiomed shares traded daily (recently around 282132.08955224). Abiomed's SIR currently stands at 2.68. In other words for every 100,000 Abiomed shares traded daily on the market, roughly 2680 shares are currently held short.
However Abiomed's short interest can also be evaluated against the total number of Abiomed shares, or, against the total number of tradable Abiomed shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Abiomed's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Abiomed shares in existence, roughly 20 shares are currently held short) or 0.0191% of the tradable shares (for every 100,000 tradable Abiomed shares, roughly 19 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Abiomed.
Find out more about how you can short Abiomed stock.
Abiomed share dividends
We're not expecting Abiomed to pay a dividend over the next 12 months.
Have Abiomed's shares ever split?
Abiomed's shares were split on a 2:1 basis on 1 October 2000. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Abiomed shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Abiomed shares which in turn could have impacted Abiomed's share price.
Abiomed share price volatility
Over the last 12 months, Abiomed's shares have ranged in value from as little as US$234.39 up to US$355.94. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Abiomed's is 1.2918. This would suggest that Abiomed's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the Automated Impella Controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; and Impella BTR, a percutaneous micro heart pump with integrated motors and sensors. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.
Frequently asked questions
Ask an Expert